Talazoparib(1207456-01-6) is a pharmaceutical compound used in the treatment of certain types of cancer, primarily breast cancer. It is not typically available in a powder form for consumer use. Talazoparib is classified as a poly (ADP-ribose) polymerase (PARP) inhibitor, which means it interferes with the activity of PARP enzymes in cancer cells, ultimately leading to the death of these cells.

Here is a general product description for Talazoparib:

Product Name: Talazoparib

Chemical Formula: C19H14F2N6O

Molecular Weight: Approximately 395.34 g/mol

Mechanism of Action: Talazoparib inhibits PARP enzymes, which are involved in repairing damaged DNA in cells. By blocking this repair mechanism, Talazoparib can cause DNA damage to accumulate in cancer cells, leading to their death.

Indications: Talazoparib is primarily used for the treatment of HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1/2 mutations. It may be prescribed when other treatment options have not been effective.

Dosage Form: Talazoparib is typically available as an oral tablet or capsule, rather than in a powder form.

Usage: Patients should take Talazoparib exactly as prescribed by their healthcare provider. It is essential to follow the dosing schedule and instructions provided by your medical team.

Side Effects: Common side effects of Talazoparib may include nausea, fatigue, anemia, low white blood cell count, and others. Your healthcare provider will monitor you for potential side effects and adjust your treatment as necessary.

Availability: Talazoparib is a prescription medication and should only be used under the guidance of a qualified healthcare professional. It is not available over the counter, and the form in which it is supplied can vary by manufacturer and country.